8-K: Jupiter Neurosciences Faces Nasdaq Delisting Threat

Jupiter Neurosciences, Inc. received notices from Nasdaq regarding non-compliance with minimum bid price and market value of listed securities requirements, risking delisting.

Summary

• Jupiter Neurosciences, Inc. (JUNS) received two notices from Nasdaq on February 26, 2026, indicating non-compliance with listing rules.
• The company failed to meet the minimum bid price requirement of $1.00 per share, as its common stock traded below this threshold for 30 consecutive business days from January 13, 2026, to February 25, 2026.
• The company also failed to maintain a market value of listed securities (MVLS) of at least $35 million for 30 consecutive business days ending February 26, 2026.
• Jupiter Neurosciences has 180 calendar days, until August 25, 2026, to regain compliance for both deficiencies.
• To regain minimum bid price compliance, the stock must close at or above $1.00 for at least 10 consecutive business days.
• To regain MVLS compliance, the company's MVLS must close at or above $35 million for at least 10 consecutive business days.
• The company's common stock will continue to trade on The Nasdaq Capital Market under the ticker JUNS without immediate effect.
• The company intends to monitor its stock price and MVLS and consider options, including a reverse stock split, to resolve the deficiencies.
• Jupiter Neurosciences also announced it may use its corporate website and social media channels (X: @jupiterneuro, Instagram: @Nugevia) to disseminate material information in the future.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a significantly negative development, as the company is in non-compliance with two key Nasdaq listing requirements, posing a material risk of delisting and reflecting poor market performance.

Positives

• The receipt of the notices has no immediate effect on the listing of the company's Common Stock, which will continue to trade uninterrupted on The Nasdaq Capital Market.
• The company has a 180-day compliance period, until August 25, 2026, to address both deficiencies.

Negatives

• The company's common stock bid price has been below the Nasdaq minimum of $1.00 for 30 consecutive business days.
• The company's market value of listed securities (MVLS) has been below the Nasdaq minimum of $35 million for 30 consecutive business days.
• Failure to regain compliance by August 25, 2026, could lead to delisting from The Nasdaq Capital Market.

Risks

• Potential delisting of the company's common stock from The Nasdaq Capital Market if compliance with minimum bid price and MVLS requirements is not regained.
• Inability to cure the deficiencies, even with potential actions like a reverse stock split.
• Uncertainty regarding the company's ability to maintain its Nasdaq listing.

Future Outlook

The company intends to actively monitor its minimum bid price and MVLS and will consider available options, including a reverse stock split, to resolve the deficiencies and regain compliance with Nasdaq Listing Rules. There is no assurance that the company will be successful in maintaining its listing.

Management Comments

• The Company intends to actively monitor its minimum bid price of its Common Stock and its MVLS, and, as appropriate, will consider available options to resolve the deficiencies and regain compliance with the Nasdaq Listing Rules, including, without limitation, effecting a reverse stock split.
• There can be no assurance that the Company will be successful in maintaining the listing of its Common Stock on The Nasdaq Capital Market.

Industry Context

StockSavvy.ai notes that non-compliance with Nasdaq's listing standards, particularly regarding minimum bid price and market capitalization, is a common challenge for smaller biotechnology or early-stage companies, especially during periods of market volatility or when clinical development faces setbacks. Such notices often signal underlying operational or financial pressures that have impacted investor confidence and valuation.

Comparison to Industry Standards

• StockSavvy.ai observes that maintaining a minimum bid price of $1.00 and an MVLS of $35 million are standard requirements for continued listing on the Nasdaq Capital Market.
• Companies like Sorrento Therapeutics (SRNEQ) and Athersys (ATHX) have faced similar delisting challenges due to failing to meet these thresholds, often leading to reverse stock splits or eventual delisting.
• The current situation for Jupiter Neurosciences places it in a category of companies struggling to meet basic market capitalization and share price stability, which is below the performance of established industry peers.

Corporate Governance

Stakeholder Impact

• Shareholders: Face increased risk of delisting, which could lead to reduced liquidity, lower stock price, and potential loss of investment if the company moves to an OTC market or ceases public trading.
• Investors: Need to monitor additional disclosure channels (website, social media) for material information.

Next Steps

• Actively monitor the minimum bid price of its Common Stock.
• Actively monitor its Market Value of Listed Securities (MVLS).
• Consider available options to resolve the deficiencies and regain compliance with Nasdaq Listing Rules, including, without limitation, effecting a reverse stock split.
• Investors should monitor the company's website, social media channels (X: @jupiterneuro, Instagram: @Nugevia), press releases, SEC filings, and public conference calls and webcasts for material information.

Key Dates

Recommendation

The company faces significant delisting risk from Nasdaq due to non-compliance with both minimum bid price and market value requirements. While there's a compliance period, the underlying issues of low share price and market capitalization suggest a lack of investor confidence and potential financial weakness. The uncertainty surrounding the ability to regain compliance, coupled with the potential for a reverse stock split (often a negative signal), makes the stock a high-risk investment with a strong likelihood of further price depreciation or liquidity issues.

Keywords

Jupiter Neurosciences, JUNS, Nasdaq, Delisting, Minimum Bid Price, Market Value of Listed Securities, MVLS, Compliance, Reverse Stock Split, SEC Filing, 8-K